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Abstract
Cryptococcosis is a globally distributed invasive fungal infection that is caused by species within 
the genus Cryptococcus which presents substantial therapeutic challenges. Although natural 
human-to-human transmission has never been observed, recent work has identified multiple 
virulence mechanisms that enable cryptococci to infect, disseminate within and ultimately kill 
their human host. In this Review, we describe these recent discoveries that illustrate the intricacy 
of host-pathogen interactions and reveal new details about the host immune responses that either 
help to protect against disease or increase host susceptibility. In addition, we discuss how this 
improved understanding of both the host and the pathogen informs potential new avenues for 
therapeutic development.
Cryptococcosis was identified in 1894, when the pathologist Otto Busse and physician 
Abraham Buschke jointly identified Cryptococcus spp. as the cause of a chronic granuloma 
of the tibial bone in a 31-year-old woman. However, human cryptococcosis only became 
recognized as a major health threat with the onset of the AIDS pandemic in the 1980s, 
during which these fungal infections became a common AIDS-defining illness in patients 
with greatly reduced T cell function (BOX 1). Although cryptococcosis is predominantly a 
disease of immunocompromised patients, a recent outbreak of cryptococcosis in otherwise 
healthy individuals in North America and Canada (now known as the Pacific Northwest 
outbreak) has focused attention on the capacity of some lineages of the fungus to act as 
primary pathogens (see below).
Since its identification, cryptococcosis has been attributed to a single fungal species, 
Cryptococcus neoformans. However, improved molecular methods led to one variety of the 
pathogen, Cryptococcus neoformans var. gattii, being classified as a distinct species, 
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Cryptococcus gattii, in 2002 (REF. 1). More recently, whole-genome sequencing-based 
analyses have high-lighted the complex evolutionary history of this group (BOX 2) and led 
to a proposal to further split C. neoformans into two species (C. neoformans and 
Cryptococcus deneoformans) and C. gattii into a total of five species (C. gattii, 
Cryptococcus bacillisporus, Cryptococcus deuterogattii, Cryptococcus tetragattii and 
Cryptococcus decagattii)2. As detailed biological comparisons between the various species 
of Cryptococcus described above have not been yet undertaken, we have adopted the simpler 
distinction into the two species C. gattii and C. neoformans throughout this article.
In this Review we describe the interactions between Cryptococcus spp. and its host, 
highlighting how this fungus subverts the host immune system to cause disease and how this 
interaction influences disease severity. We also discuss potential therapeutic avenues 
revealed by the improved understanding of these host–pathogen interactions.
Cryptococcus transmission and disease onset
In the environment, cryptococci reside in diverse ecological niches (BOX 3). Both C. 
neoformans and C. gattii are abundant in decaying material within hollows of various tree 
species, although C. gattii has been suggested to favour trees with waxier cuticles (such as 
the Douglas fir Pseudotsuga menziesii)3, 4. Furthermore, C. neoformans is globally 
distributed, whereas C. gattii has classically been viewed as a tropical or subtropical fungus. 
However, increased surveillance has now identified environmental reservoirs for C. gattii in 
the Northern USA, Canada and Northern Europe, indicating that this species may also have 
a wider ecological range than previously recognized.
C. neoformans is particularly abundant in avian excreta4, 5, and its association with feral 
pigeons could be a major source of infection in densely populated urban areas. In addition, 
both C. neoformans and C. gattii can survive and replicate in free-living amoebae and soil 
nematodes, and it is possible that these alternative hosts may have an important role in 
determining the distribution and virulence of different cryptococcal lineages around the 
world (BOX 3).
With the exception of very rare iatrogenic6 or zoonotic7 transmission events, naturally 
acquired cases of cryptococcosis are thought to start with inhalation of fungal cells from the 
environment. Within the lung, Cryptococcus spp. can cause pneumonia in 
immunosuppressed patients, but in immunocompetent hosts the fungal cells are either 
cleared by the immune system or establish an asymptomatic latent infection. On subsequent 
immunosuppression, this latent infection can then disseminate to other tissues, most notably 
the central nervous system (CNS). Once established in the CNS, cryptococcosis causes an 
overwhelming infection of the meninges and brain tissue that is frequently accompanied by 
raised intracranial pressure; without rapid and effective treatment, CNS infection is 
invariably fatal. Despite intensive investigations, it remains unclear whether reactivation and 
dissemination of long-term latent pulmonary infection is a more important cause of 
cryptococcosis in patients than de novo acquisition from the environment, but experiments in 
animal models indicate that both routes can cause lethal disease.
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Exposure to C. neoformans is common in humans, as most individuals produce antibodies 
against this fungal species by school age8. During active growth, cryptococcal cells are too 
large to penetrate deep into the human lung and thus the initial inoculum is thought to 
comprise either desiccated cells or spores. The relative contribution of these two cell types to 
the burden of disease remains unclear, largely owing to technical challenges associated with 
generating and purifying spores. However, recent studies have demonstrated that lethal brain 
infections can develop from spore inocula, that spores are readily phagocytosed by host 
immune cells and, interestingly, that rising humidity markedly increases spore viability9–11. 
Thus, as with other fungal pathogens such as Coccidioides immitis, environmental 
conditions may be an important factor in regulating human cryptococcal exposure.
Cryptococcal pathogenesis
Traditional virulence factors produced by Cryptococcus spp. (such as the capsule and 
melanin) and changes in fungal growth due to the host temperature (37 °C) have been 
previously reviewed in great detail (see for example REFS 12, 13). Instead, in this section of 
the Review, we focus on recently emerging concepts in cryptococcal pathogenesis.
Fungal morphology
Whether derived from spores or yeast cells, upon inhalation into a mammalian host all 
cryptococci transition to or maintain a yeast form. When grown under laboratory conditions, 
Cryptococcus cells are round and 5–7 µm in diameter. However, their cell size, structure and 
characteristics can vary dramatically within the host.
The best-characterized atypical morphology of Cryptococcus cells is the titan cell14 (FIG. 
1). Titan cells are greater than 12 µm in diameter (excluding the capsule), polyploid, have 
highly crosslinked capsules and a thickened cell wall15, 16. Recent studies have shown that 
titan cells contain elevated levels of chitin. This polysaccharide is recognized and cleaved by 
host chitinases, which induces a detrimental adaptive immune response (see below)17. 
Intriguingly, the polyploidy observed in titan cells enhances genetic adaptation to the 
stressful host environment, resulting in increased within-host survival18.
In addition to the large titan cells, unusually small cryptococcal cells have also been 
observed19, 20 (FIG. 1). These socalled drop or micro cells are only 2–4 µm in size, despite 
having a thickened cell wall, and seem to be adapted for growth in macrophages. At present, 
little is known about this cell type, although they seem to be relatively metabolically inactive 
and therefore may have an important role during the latent stage of disease.
In the environment or under laboratory conditions, cryptococci can also grow as hyphae 
(during sexual reproduction) or pseudohyphae, but unlike other pathogenic fungi these 
morphologies are not seen in human infections21. Recent studies overexpressing the 
transcription factor Znf2, a master regulator that triggers the transition from yeast to hyphal 
growth, showed that the hyphal form elicits a robust protective immune response and is 
readily cleared by the host22, 23, perhaps explaining why filamentous morphologies are not 
seen in mammalian infections. Interestingly, however, hyphal cryptococci are protected from 
predation by free-living amoebae24, and thus mammalian and amoebal hosts presumably 
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exert opposing selective pressures on this aspect of cryptococcal morphology (with 
mammalian hosts favouring the existence of the yeast forms and amoebae favouring hyphal 
forms).
Fungal ageing
Even within a clonal infection, not all cryptococcal cells are equal. For example, the age of 
individual cryptococcal cells has emerged as a factor that affects survival in the host and 
subsequent pathogenesis25. Older cells present in the initial infection, referred to as 
founder cells, are better able to resist phagocytosis and killing by phagocytes and are 
resistant to antifungal drugs. This increased resistance to phagocyte killing and antifungals is 
potentially due to changes in cell wall structure26 and results in the accumulation of founder 
cells in the brain at a higher frequency than young cells27.
Population-wide signals
In bacterial infections, quorum sensing is a well-known mechanism that regulates 
virulence according to population density. Interestingly, emerging data suggest that quorum 
sensing may also have an important role during cryptococcal pathogenesis. For example, a 
quorum sensing effect, mediated by an oligopeptide with 11 amino acids, was identified 
using mutations in the global repressor Tup1. Notably, although Tup1 is present in several 
species, the quorum sensing effect mediated by this oligopeptide seems to only occur in C. 
neoformans28. However, more recently a different signalling molecule, pantothenic acid, 
was shown to mediate quorum sensing both between different cryptococcal strains and 
between cryptococci and other, relatively distantly related fungal species29. The adhesin 
Cfl1 has also been shown to modulate colony morphology in a paracrine manner30. 
Activation of the hyphal regulator Znf2 induces expression of this adhesin, some of which is 
shed into the environment and triggers neighbouring cells to activate Znf2, leading to a 
positive feedback loop. Thus, cryptococci may communicate locally using a range of 
chemical messengers31.
Perhaps most unique is the observation that light-sensing pathways may also be important 
for virulence in Cryptococcus spp., as deletion of either BWC1 or BWC2, which encode two 
transcription factors that control fungal responses to light, reduces virulence in a mouse 
model of infection32. In the dark, Bwc1 and Bwc2 bind to DNA and repress genes involved 
in filamentation. However, upon light activation, they release this inhibition, leading to 
filamentation and upregulation of ultraviolet-resistance pathways. Thus, it is possible that an 
additional function of these two proteins is to detect darkness and prevent inappropriate 
filamentation within the host, which would induce a potent immune response and pathogen 
clearance.
Host immunity and pathogen subversion
One of the most remarkable discoveries of recent years has been the extent to which 
cryptococci can manipulate the host immune response to dampen inflammation, avoid 
killing by phagocytic cells and ultimately disseminate into the CNS.
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Inflammatory perturbation
In general, environmental fungi trigger a potent pro-inflammatory response on entry into the 
human host. By contrast, cryptococci seem to be immunologically inert, driving much lower 
levels of pro-inflammatory cytokine release in vitro than other human fungal pathogens such 
as Candida albicans33. This immunological masking relies on various pathogen traits (FIG. 
1).
First, the complex carbohydrates glucuronoxylomannan (GXM) and galactoxylomannan 
(GalXM), which make up most of the cryptococcal capsule, are extensively shed during 
infection and directly dampen inflammation by suppressing the pro- inflammatory nuclear 
factor-κB (NF-κB) pathway and driving down levels of pro-inflammatory cytokines such as 
tumour necrosis factor (TNF)34. In addition, emerging data indicate that cryptococcal chitin 
and its derivatives can also alter host inflammatory responses during infection17. Second, 
Cryptococcus spp. block dendritic cell maturation by reducing both major 
histocompatibility complex class II (MHC class II)-dependent antigen 
presentation and inhibiting the production of the pro-inflammatory cytokines interleukin-12 
(IL-12) and IL-23 (REF. 35). Last, via a series of as-yet poorly characterized steps, 
cryptococci can partially repolarize the immune response, at least in mice, from a strong T 
helper 1 response (TH1 response) towards a weaker TH1 or often a TH2 response, 
which is less effective at fungal clearance17, 36–38.
Collectively, these mechanisms generate an environment that is dominated by anti-
inflammatory markers such as IL-4 and IL-33 (REFS 39–41), which, as a consequence, 
reduce cryptococcal killing by the immune system38, 42. Therefore, modulating natural 
immune responses to cryptococcal infection towards a more pro-inflammatory profile offers 
one potential avenue for treatment. However, such approaches need to be carefully managed 
to avoid the potentially fatal immune ‘over reactions’ that can accompany overt 
inflammation, which can be just as life-threatening as the original infection (BOX 4).
Avoidance and escape from phagocytes
Following entry into the lung, the first immune cell typically encountered by cryptococci is a 
phagocyte such as an alveolar macrophage or dendritic cell. However, cryptococci are 
predisposed to avoid killing by these cells, owing to their long evolutionary history of 
exposure to environ-mental amoebae (BOX 3). Several cryptococcal virulence factors, such 
as capsule synthesis, melanization and urease secretion combine to protect the fungus 
from the harsh environment within phagocytic cells by neutralizing reactive oxygen species 
and pH, allowing it to survive and proliferate within such cells43 (FIG. 2).
More recently, it has also become clear that cryptococci exhibit a remarkable strategy to 
escape from phagocytes. This process, which has been labelled vomocytosis or extrusion, 
involves inducing the fusion of the phagosomal membrane with the plasma membrane, 
resulting in the expulsion of the fungi from the phagocyte44–48. In addition, either this 
process or a closely related one can drive the direct ‘lateral transfer’ of cryptococci between 
host cells44, 45. However, the underlying mechanisms of both of these remarkable processes 
remain unknown.
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Although cryptococci employ several mechanisms to resist phagocytosis (such as the 
production of titan cells15, 49 and the assembly of a thick polysaccharide capsule), fungal 
uptake by phagocytes can still occur. However, if uptake does occur, cryptococci perturb 
both phagosome maturation50 and modify the phagosome membrane to allow nutrient 
exchange and ultimately escape from the host cell51, 52. Notably, these effects depend on 
fungal virulence factors such as laccase and phospholipase B1. These enzymes have been 
classically thought of as having direct structural roles in melanin synthesis and membrane 
lipid modification, respectively, but the observation that they also mediate escape from 
phagocytosis suggests that they may also have more subtle roles in modifying host signalling 
events36, 53, 54.
Dissemination and entry into the CNS
A key feature of cryptococcal pathogenesis involves the exit of Cryptococcus spp. from the 
lungs into peripheral blood circulation and entry into the CNS compartment. The CNS is 
both an immune-privileged site and a highly sterile environment, and thus Cryptococcus spp. 
must have evolved potent methods to traverse the blood–brain barrier and subsist in 
the CNS.
There are three proposed mechanisms to penetrate this impervious barrier. First, the 
Cryptococcus cells could force their way between the tight junctions of the endothelial cells 
in a process known as paracytosis, by using proteases such as Mpr1 to promote 
transendothelial migration55 (FIG. 2). Impressively, when MPR1 was introduced into 
Saccharomyces cerevisiae, a fungus not normally able to penetrate the blood–brain barrier, 
S. cerevisiae gained the ability to cross endothelial cells in an in vitro transwell assay, 
although the target of Mpr1 remains unknown. Additional studies using powerful intravital 
imaging techniques demonstrated that cryptococci cross the blood–brain barrier by inducing 
an embolic event in the microvasculature that lines the brain56. In essence, the initial 
‘capture’ of the fungus within the brain is passive, with the relatively large cells becoming 
trapped at points where the blood vessel narrows. However, following the initial passive 
arrest, cryptococcal migration into the brain tissue is an active process, as it occurs only with 
live fungal cells and depends on the secretion of the cryptococcal enzyme urease57. To date, 
the part played by urease in this process remains enigmatic; however, because urease 
produces ammonia, which is toxic to mammalian cells, it is possible that urease acts to 
locally weaken the endothelial vessel wall, facilitating fungal entry.
The second mechanism of blood–brain barrier penetration is transcytosis58 (FIG. 2). 
Hyaluronic acid situated on the surface of the cryptococcal cell binds to CD44 on the 
luminal endothelium, attaching the fungus to the host cell59. This binding then induces 
protein kinase C-dependent actin remodelling in the host cell, leading it to engulf the 
attached Cryptococcus cell60. Interestingly, recent work has revealed that the high levels of 
inositol present in the brain act as a trigger for this process, increasing hyaluronic acid 
expression by the fungus61.
Finally, Cryptococcus spp. is postulated to cross the blood–brain barrier by ‘hitchhiking’ 
within host phagocytes, in what is known as the ‘Trojan Horse’ hypothesis (FIG. 2). This 
hypothesis is supported by the observation that depletion of alveolar macrophages in mice 
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significantly reduces cryptococcal dissemination to the CNS62, whereas infecting monocytes 
in vitro and transferring the cells into naive hosts substantially increases cryptococcal 
accumulation in the brain compared to transfer-ring Cryptococcus spp. directly; both studies 
support the notion that phagocytes act as fungal carriers that breach the blood–brain 
barrier63. Although paracytosis, transcytosis and Trojan Horse models are all fundamentally 
different, it is reasonable to conclude that elements of each of these models are readily 
observed and likely occur in concert during natural infection.
Not much is known about the physiology of Cryptococcus spp. after it has traversed the 
blood–brain barrier. However, a recent study of the transcriptome of cryptococcal yeasts 
isolated from patient samples of cerebrospinal fluid (CSF) offers some clues64. Most 
notably, Cryptococcus spp. are remarkably metabolically active in the CSF in vivo , showing 
strong upregulation of stress response genes and genes encoding enzymes that are involved 
in core metabolic processes; this is somewhat surprising, given that the CSF is a relatively 
nutrient- depleted medium. By contrast, Cryptococcus spp. growing in ex vivo CSF do not 
seem to be metabolically active, suggesting that the permanent cycling of CSF in vivo leads 
to a significantly higher nutrient content in the CSF than suggested by the analysis of ex vivo 
samples.
The modified fungal metabolism observed in the CSF is likely to have significant 
implications for pathogenesis. For instance, capsule synthesis is energetically highly 
demanding, and there is a positive correlation between capsular size and severity of clinical 
disease65. Therefore, these data suggest that yeasts in a more active metabolic state may 
drive more aggressive CNS infections. Furthermore, fungal cells in different metabolic states 
are likely to give rise to different immune responses, which may also affect disease severity. 
In agreement with this possibility, the presence of a pro-inflammatory response in the CSF 
consisting of an interplay of robust TH1 cytokines (IFNγ and IL-6), TH2 cytokines (IL-4 and 
IL-10) and TH17 cytokines (IL-17) has recently been shown to be highly predictive of more 
rapid clearance of infection and consequently improved survival in patients with HIV-
associated cryptococcal meningitis66 (BOX 4).
Division of labour
The extent to which cryptococci can exploit phagocytic cells as a host has been strongly 
highlighted by the unusual cluster of cryptococcal disease now known as the Pacific 
Northwest outbreak67. Although cryptococcosis is typically a disease of 
immunocompromized hosts, almost all of the human and animal cases within the Pacific 
Northwest outbreak were immunocompetent hosts who became infected with near clonal 
strains of C. gattii from the VGII lineage. Both the epidemiology and aetiology of these 
infections differ from classical cryptococcosis (typically caused by C. neoformans in HIV-
positive individuals)33, 68, which has led to vigorous efforts to establish the underlying 
mechanism driving virulence in the C. gattii VGII lineage.
The ability of the C. gattii VGII lineage to establish disease in individuals with a fully 
functional immune system seems to stem from a capacity to replicate extremely rapidly in 
host phagocytes (FIG. 2), presumably overwhelming the host before adaptive immunity can 
be triggered69. Recent data have revealed that this rapid proliferation is, in turn, driven by a 
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remarkable mechanism of division of labour. In response to reactive oxygen species 
generated by the phagocyte, intracellular cryptococcal cells adopt different fates; some stop 
growing and acquire an unusual morphology that is characterized by extensive tubularization 
of their mitochondria, whereas neighbouring cells do not undergo this transition. Notably, 
via a mechanism that remains unclear, the cells that undergo the morphological switch then 
protect neighbouring cryptococci from the antimicrobial activity of the host phagocyte, 
enabling them to replicate rapidly and thereby maximizing the proliferative capacity of the 
population as a whole70. These data highlight the Cryptococcus–phagocyte interaction as a 
key aspect of infection that may offer powerful opportunities for therapeutic intervention in 
both C. neoformans and C. gattii infections.
Anti-cryptococcal therapeutics
Despite its global distribution, treatment of crypto coccosis remains a major challenge, 
relying on a limited arsenal of decades-old therapeutic agents. Furthermore, therapeutic 
outcomes are generally poor and even with amphotericinbased therapy (to target 
Cryptococcus spp.) and widespread access to anti-retroviral therapy (to target HIV, as most 
patients are immunocompromised patients with HIV), acute (that is, within 3 months) 
mortality following cryptococcal meningo encephalitis remains at 35–40%, both in resource-
rich and resource-poor settings71, 72.
Currently used drugs
Only three classes of antifungal agents are currently used to treat cryptococcosis: polyenes 
(such as amphotericin B), azoles (such as fluconazole) and the pyrimidine analogue 
flucytosine (5-FC) (FIG. 3).
The cornerstone of treatment of cryptococcal meningoencephalitis is amphotericin B 
deoxycholate (AmBd), developed in the 1950s, which exerts its fungicidal effect both by 
binding to ergosterol in the cryptococcal cell wall (generating pores in the cell membrane) 
and by inducing cell death via oxidative damage73–75. AmBd is sometimes combined with 
5-FC. The mechanism of action of 5-FC is deamination by the fungal enzyme cytosine 
deaminase into 5-fluorouracil (5-FU), which then acts through two pathways: 5-FU can be 
converted by cellular pyrimi-dine-processing enzymes into 5-fluorodeoxy uridine 
monophosphate, which inhibits thymidylate synthetase and blocks DNA synthesis; or it can 
be converted into 5-fluorouridine triphosphate, which is incorporated into RNA, thereby 
disrupting protein synthesis and leading to growth arrest. AmBd and 5-FC act synergistically 
to produce the fastest rates of fungal clearance from CSF76, and combination therapy results 
in a significant improvement in 10-week survival of patients compared with treatment with 
AmBd alone77. This combination remains the recommended ‘gold standard’ induction 
treatment in international treatment guidelines78 but presents substantial challenges in 
resource-poor settings, as AmBd must be administered intravenously and has notable 
toxicities. In addition, AmBd and 5-FC are not widely available in countries where 
cryptococcosis is most prevalent79.
To circumvent the problems associated with AmBd and 5-FC combination therapies, the 
combination of fluconazole with 5-FC (which can both be administered orally) and shorter 
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(that is, 1-week long) AmBd-based induction treatment is being compared to the standard 2-
week induction regimens in a multi-site Phase III trial in Africa80. Fluconazole is being 
tested because it has good oral bioavailability and excellent CSF penetration; these 
properties also make it a good candidate for main tenance therapy after initial treatment. 
Fluconazole inhibits the fungal cytochrome P450 enzyme 14α-demethylase, which is 
required for conversion of lanosterol to ergosterol, an essential component of the fungal cell 
membrane. However, fluconazole is a fungistatic (rather than fungicidal) and so is less 
effective at pathogen clearance and not recommended for initial therapy.
Drug resistance
Resistance to antimicrobials is a growing issue in infectious disease, and cryptococcosis is 
no exception. Although environmental resistance is rare, acquired resistance has been 
observed with all three classes of antifungals in use against Cryptococcus spp.
Polyene resistance is uncommon but has been reported in C. neoformans, with mutations in 
sterol synthesis and therefore alteration of the target site noted in isolates with extensive 
exposure to AmBd81. For 5-FC, single mutations at varying points along the 5-FU 
intracellular pathways lead to in vitro and clinical resistance. Therefore, monotherapy with 
5-FC is not appropriate due to rapid selection of resistant Cryptococcus spp. leading to 
treatment failure; the drug is thus always combined with either AmBd or fluconazole. 
Fluconazole, like 5-FC, is fungistatic, making it liable to evolution of secondary resistance 
during prolonged treatment82. A key mechanism of resistance against fluconazole is the 
selection of intrinsically resistant cryptococcal subpopulations83 that carry specific 
chromosomal disomies84 and thus overexpress ERG11 (which encodes the fluconazole 
target enzyme lanosterol-14α-demethylase85) or have enhanced drug efflux by the ATP-
binding cassette (ABC) transporter- encoding gene C. neoformans anti-fungal resistance 1 
(CNAFR1)86.
New drugs
Given the ongoing high global incidence and mortality from cryptococcal 
meningoencephalitis, the dearth of drugs, together with toxicity and the potential for 
development of resistance, there is an urgent need for new drugs. Recent activity in this area 
has begun to highlight potential routes either for the discovery of new antifungals or for the 
repurposing of existing molecules showing anticryptococcal activity (FIG. 3).
An ideal antifungal drug should specifically target the fungus and not the host to avoid host 
cell toxicity; this is challenging given that fungal cellular processes are more closely related 
to mammals than those that are targeted by common antimicrobials, such as the ones used to 
target bacterial pathogens. Furthermore, an ideal antifungal drug should target either a 
virulence factor or a fungal component that is essential for fungal viability. Such a drug 
should be fungicidal when used alone or when combined with the widely available 
fluconazole, it should have good oral bioavailability (allowing it to be readily administered 
even in resource-poor settings) and should be able to enter cryptococcal niches within the 
host (such as phagocytes and the CNS).
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One obvious target of such a drug is the cryptococcal cell wall. Unfortunately, the latest 
class of antifungals that are active against the cell wall, β-1,3D–glucan synthase inhibitors 
(known as echinocandins), have no substantial anti-cryptococcal activity. However, synthesis 
of another cell wall component, glycosylphosphatidyl inositol (GPI)-anchored 
mannoproteins, is inhibited by the orally active experimental molecule E1210, which has in 
vitro activity against Cryptococcus spp. and other medically relevant fungi (such as Candida 
and Scedosporium spp.) and is currently in preclinical development87.
Further along the development pipeline is VT-1129, an ergosterol synthesis inhibitor 
(available for oral administration) which shows good CNS penetration and is fungicidal in 
mouse models of Cryptococcus spp. infection. VT-1129 blocks the activity of CYP51, an 
essential enzyme in the pathway that produces ergosterol, and is currently entering human 
clinical trials (for further information see the Viamet website). Also in Phase I trials is the 
arlyamidine T-2307, which targets the fungal mitochondrial membrane88. T-2307 is a 
fungicidal injectable compound that shows comparable efficacy to AmBd in mouse models 
of infection.
Given the lack of market forces driving pharmaceutical development for a neglected disease 
such as cryptococcal meningoencephalitis, an alternative, cheaper and more expedient 
strategy in drug development is the repurposing of drugs that were originally developed for 
other conditions. Recently developed high-throughput screening techniques have advanced 
the repurposing effort. One such powerful tool is chemical-genetic profiling, whereby large 
collections of cryptococcal-knockout mutants, for which the function of a particular pathway 
is compromised, are screened against a library of small molecules89, and the growth 
behaviour of the screened strain (that is, increased or decreased susceptibility) is then 
recorded. A recent application of this technique with 1,448 knockout mutants of C. 
neoformans demonstrated distinct differences in drug susceptibility between this species and 
the model organism S. cerevisiae which, until now, has been the standard choice for such 
screens89. As proof-of-principle, this approach has identified a number of molecules that 
synergize strongly with fluconazole to inhibit ergosterol synthesis in C. neoformans and 
which are now being further investigated for potential clinical applicability. Moreover, this 
method has the additional advantage of providing information on the mechanism of action of 
lead compounds and can therefore identify both potential new drugs and potential new drug 
targets.
A more classical approach is to screen for compounds that trigger fungal cell lysis (detected 
by the release of adenylate kinase, a cytosolic enzyme, into the medium) or that alter ATP 
content90 (a particularly effective approach for identifying compounds that are antifungal 
under starvation conditions). This strategy has identified a collection of off-patent drugs91 
with anticryptococcal activity that are additive or synergistic with fluconazole. These include 
drugs as diverse as amiodarone (a cardiac anti-arrhythmic drug), phenothiazines (widely 
used antipsychotics) and tamoxifen (an oestrogen antagonist used to treat breast cancer). 
Illustrating the utility of these approaches, tamoxifen in combination with fluconazole 
decreased the C. neoformans burden in the brain by ∼1 log10 CFU per gram of brain tissue, 
in a mouse model of infection92. Finally, another candidate that has emerged from 
repurposing screens is the antidepressant sertraline which is fungicidal, has high CNS 
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penetration and seems to target fungal protein synthesis through an unknown mechanism93. 
Sertraline is currently being evaluated in combination with AmBd and fluconazole in a 
Phase II/III clinical trial94.
Outlook
The past 5 years have seen a remarkable revolution in our understanding of cryptococcosis. 
A deeper understanding of the natural ecology and an appreciation of the genetic and 
phenotypic diversity of this group of pathogens is transforming our understanding of 
cryptococcal pathogenesis. Meanwhile, huge progress has been made in understanding the 
host immune response to infection and how this process is hijacked by cryptococci to drive 
latency, dissemination and proliferation. However, despite these advances, cryptococcosis 
remains a major worldwide killer, causing hundreds of thousands of deaths per year, and the 
anticryptococcal drug arsenal remains limited. To address this, there is renewed focus on 
translational research to discover and develop new therapeutic agents and to evaluate new 
therapeutic strategies in a clinical setting. While progress is being made in this respect, more 
is urgently required, and advances in understanding the pathogenesis of Cryptococcus spp. 
offer new opportunities for developing therapeutics beyond the traditional approaches of 
killing the fungal cell or preventing its replication. In particular, the rapidly expanding 
understanding of the Cryptococcus–host interface opens up new avenues for potential 
therapy development; for instance, in modifying host pro-inflammatory responses, 
augmenting phagocytic clearance of the fungus, disrupting population signalling or 
preventing migration to the CNS. Together, such approaches offer the hope of significantly 
reducing the huge global burden of infection and making fatal cryptococcosis a disease of 
the past.
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Glossary
Pacific Northwest outbreak
An unusual cluster of cryptococcal disease in otherwise healthy (rather than 
immunocompromised) individuals. First identified on Vancouver Island, British Columbia, 
in 1999 (and hence originally called the Vancouver Island outbreak), both the causative 
organism and cases of human and animal disease have now expanded into mainland Canada 
and the northwestern USA, prompting a renaming of the outbreak.
Iatrogenic
Caused by medical treatment. For instance, infections due to contaminated surgical 
instruments.
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Zoonotic
A disease transmitted from animals to people.
Polyploid
Having multiple (that is, more than two) sets of homologous chromosomes.
Founder
The initial, small group of individuals that seeds a new population. For instance, the 
inoculum that starts an infection, or the first individuals to arrive on a new island habitat.
Quorum sensing
The regulation of gene expression or behaviour in response to changes in the local 
population size.
Paracrine
A signal that acts close to where it is produced, for instance on neighbouring cells.
Filamentation
The growth of an organism by elongation without division.
Major histocompatibility complex class II
(MHC class II). Molecules that are expressed on the surface of professional antigen-
presenting cells (such as macrophages and dendritic cells) and present extracellular antigens 
to the immune system to coordinate an immune response.
T helper 1 response
A response by one subtype of CD4+ helper T (TH) cell that is generally provoked by 
intracellular pathogens. TH2 responses, by contrast, are typically involved in the elimination 
of parasitic worms, harmful allergic responses and dampening of TH1-mediated 
inflammation. In the context of cryptococcal infection, TH1 responses are widely thought to 
be protective, and TH2 responses to be detrimental.
Coalescence analyses
An evolutionary analysis method in which genetic drift is ‘.played backwards’. to calculate 
common ancestry of individuals within a population and thereby estimate lineage branch 
points within an evolutionary phylogenetic tree.
Bipolar mating
A system to control sexual reproduction that relies on a single genetic locus at which 
individual organisms can carry one of two alleles, effectively generating a species with two 
sexes.
Diploid
Having two homologous sets of chromosomes, one from each parent.
Aneuploid
Having an ‘.unbalanced’. set of chromosomes; for instance, having only a single copy of one 
chromosome in an otherwise diploid genome.
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Melanization
The production of the dark, insoluble pigment melanin, which provides protection from high 
energy radiation and reactive oxygen molecules.
Blood–brain barrier
A specialized endothelial barrier that prevents the entry of cells or large molecules into the 
central nervous system.
Paracytosis
Transitioning between tissues by moving between, rather than through, adjacent cells.
Transcytosis
Transitioning between tissues by moving directly through cells, rather than between adjacent 
cells.
Hyaluronic acid
An abundant, high-molecular-weight polysaccharide that forms part of the extracellular 
matrix, particularly in neural tissue.
Cerebrospinal fluid
(CSF). A clear fluid produced in the brain that bathes the central nervous tissue and is slowly 
turned over.
Regulatory T cells
A type of T cell that functions to regulate the immune system, typically by suppressing the 
function of pro-inflammatory effector T cells.
Fungicidal
An antimicrobial agent that kills fungi, rather than simply preventing growth.
Fungistatic
An antimicrobial agent that prevents fungal growth, but does not kill the organism.
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Box 1
Clinical cryptococcosis
Epidemiology
Because cryptococci are capable of extended latency in host cells43 and most humans 
encounter the organism in early childhood8, it has been assumed that most clinical cases 
represent reactivation of a longstanding, asymptomatic infection (triggered, for instance, 
by falling CD4+ T cell counts in HIV-infected individuals). The proportion of clinical 
disease representing reactivated latent disease versus primary infection is unknown in 
HIV-positive individuals, but a study in patients with cryptococcosis following solid-
organ transplantation found that only 52% of infections are due to reactivation95, 
suggesting that the classical view of cryptococcosis as a reactivating infection may not be 
accurate.
Emerging data are also highlighting the heterogeneity of cryptococcal disease worldwide, 
as illustrated by the prevalence of serum cryptococcal antigen (CrAg) in HIV-positive 
cohorts in different countries (see the figure, which displays the highest recorded 
prevalence per country). In addition, it is now clear that there is also considerable global 
heterogeneity in the fungal population structure. For example, Cryptococcus neoformans 
var. grubii (serotype A) is the predominant global cause of HIV-associated cryptococcal 
meningoencephalitis, but in China this organism frequently infects apparently 
immunocompetent hosts96. Similarly, particular lineages of C. neoformans vary both in 
virulence97–99 and in their ability to infect immunocompromised or immunocompetent 
individuals100. In the near future, intensive whole genome sequencing efforts for both 
cryptococcal isolates and affected patients may be able to explain the relative contribution 
of host and pathogen genotypes underlying these global patterns of disease.
Susceptibility
In contrast to other systemic fungal infections (such as candidiasis), relatively little is 
known about genetic risk factors for cryptococcosis. However, recent allelic association 
studies have shown that apparently immunocompetent individuals with cryptococcosis 
are significantly more likely to have defects in mannose-binding lectin101 or to be 
homozygous for the 232I allele of Fc γ receptor 2B (Fc γR2B)102, although these 
polymorphisms are common and thus, on their own, are clearly not sufficient to render an 
individual fully susceptible to cryptococcosis. Therefore, subtle defects in the innate 
immune response to fungi may underlie at least some cases of C. neoformans infection in 
otherwise healthy individuals. Similarly, in HIV-positive patients, allelic variation in a 
different FcγR, FcγR3A, also correlates with susceptibility103. In this case, individuals 
with a higher affinity receptor variant are at greater risk of infection, perhaps indicating 
that efficient uptake of the pathogen may actually aid dissemination and drive more 
severe disease. This is particularly striking because the same is true from the pathogen 
perspective: cryptococcal strains that are more avidly phagocytosed drive more 
aggressive disease and carry a higher risk of death in patients104. Thus, excessive 
phagocytosis as a result of either host or pathogen variation seems to drive cryptococcal 
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dissemination, strongly supporting the Trojan Horse model of pathogen spread (see the 
main text).
Diagnosis
Diagnosis of cryptococcosis relies on detection either of the organism itself or its shed 
capsular glucuronoxylomannan (GXM) polysaccharide in serum or cerebrospinal fluid. 
This has been hugely facilitated by the introduction of the point-of-care lateral flow 
cryptococcal antigen assay, which is cheaper and more sensitive than earlier serological 
tests105. This test can detect very early dissemination and has facilitated cohort studies 
across the world, revealing a 2–21% prevalence of cryptococcal antigens in HIV-infected 
patients. As an increasing proportion of cases of cryptococcal meningoencephalitis are 
now presenting as unmasking of latent infection following therapy (that is, the 
appearance of clinical symptoms following immune reconstitution by antiretroviral 
treatment), wider implementation of a ‘screen-and-treat’ approach is cost effective as a 
public health intervention and has been demonstrated to reduce mortality in African HIV 
cohorts in the first year on antiretroviral therapy106.
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Box 2
The evolutionary history of cryptococci
The two Cryptococcus species, Cryptococcus gattii and Cryptococcus neoformans, 
probably diverged from a common environmental saprophyte ancestor around 30–40 
million years ago107, 108 (see the figure). For C. neoformans, extensive genetic data now 
indicate a common origin in sub-Saharan Africa5, 109110. The observation that most non-
African C. neoformans populations are nearclonal supports a model in which 
recombining African populations of cryptococci occasionally dispersed to other parts of 
the globe. Coalescence analyses indicate that almost all of these events have 
occurred within the past 5,000 years, suggesting the potential involvement of human or 
avian migrations in this process5.
Probing the origin and diversity of C. gattii has proven more challenging. There is a 
growing consensus that the evolutionary origins of this species lie within Australia and 
South America, as most dispersed lineages of C. gattii are near clonal (such as the lineage 
responsible for the Pacific Northwest outbreak) but always cluster with Australian and 
South American isolates during phylogenetic analyses, with an estimated origin within 
the past 50,000 years111–113. A recurrent theme therefore seems to be that local 
populations of C. gattii in endemic areas (such as Brazil) undergo continual 
recombination, which occasionally results in a new recombinant lineage that disperses 
and expands rapidly by means of clonal growth (either asexual cell division or same-sex 
mating)111, 112, 114.
Both species of Cryptococcus have a bipolar mating system in which cells are either 
mating type a (MATa) or mating type-α (MATα) (reviewed in REF 115). Classical 
mating involves genetic exchange between a MATa and MATα strain, followed by 
normal Mendelian segregation of alleles. However, both species of cryptococci are also 
capable of same-sex mating in which two strains of the same mating type can exchange 
genetic material114, 116. In addition, diploid and aneuploid strains are not 
uncommon117, 118, and inter- and intra-species hybrids can be found both in the 
environment and in patients119, 120. Thus, the global population structure of these 
pathogens reflects a complex mix of diversity generating recombination and aneuploidy, 
coupled with highly clonal amplification steps during dispersion events.
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Box 3
The evolution of virulence in cryptococci
Opportunistic pathogens represent an evolutionary enigma: why has natural selection 
driven the acquisition of often highly specific virulence factors when most of the 
population remain as exclusively environmental organisms for their entire existence? This 
conundrum is particularly pertinent for cryptococci, which are abundant in the 
environment but are remarkably well suited to survive in a human host.
A compelling hypothesis to resolve this conundrum is that of accidental pathogenesis 121. 
This hypothesis proposes that cryptococcal pathogenesis does not result from direct 
selection for virulence within a mammalian host, but rather by the evolution of traits 
(which happen to be advantageous in mammals) in response to other selective pressures 
in both environmental and animal niches. So, for example, the complex polysaccharide 
capsule, laccase activity and the ability to synthesize melanin, all of which are 
Cryptococcus spp. virulence factors, are likely to offer protection against environmental 
pressures such as desiccation or exposure to ultraviolet light122, or aid in the colonization 
of plant hosts123. Similarly, cryptococci can replicate not only within vertebrate 
phagocytes, but also in free-living phagocytic amoebae124 (see the figure). Despite the 
enormous evolutionary distance between vertebrates and amoebae, many of the 
mechanisms used by phagocytic white blood cells to kill pathogens (for example, the 
generation of reactive oxygen species or the secretion of antimicrobial peptides) are 
identical to those used by amoebae to digest ingested prey. Thus, over millions of years, 
cryptococci have been selected to evolve strategies that facilitate fungal growth and 
persistence within amoebae that coincidentally also enable their survival within 
phagocytes. Such strategies include not only stress-tolerance approaches, such as 
resistance to reactive oxygen species125, but also elaborate mechanisms to regulate 
expulsion from host cells46, 47.
In addition, Cryptococcus spp. have a remarkable ability to perturb adaptive immunity, 
preventing complete fungal clearance and resulting in latent infections19, 126. Perhaps the 
ability to remain latent without perturbing their host is the strongest evidence for host 
adaptation by cryptococci. Because only higher vertebrates have adaptive immune 
systems, Cryptococcus spp. probably evolved these properties under the selective 
pressures of reptilian, avian or mammalian hosts within the environment, which also 
explains the diverse range of animals that are susceptible cryptococcosis.
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Taken together, these observations suggest that interactions with both soil 
microorganisms (such as amoebae and nematodes) and vertebrates probably have a 
crucial role in the virulence potential of Cryptococcus spp. (reviewed in REF. 127). 
Intriguingly, laboratory studies have shown that selection pressure by amoebae can 
rapidly select for resistant, pseudohyphal forms of cryptococci23. These forms are 
attenuated in mammalian hosts and consequently frequently revert to yeast upon entry 
into a vertebrate host. Thus, rapid microevolutionary events may have an important role 
in driving cryptococcal pathogenesis in different hosts.
The paradigm of accidental pathogenesis extends beyond cryptococci to other fungal128 
and even bacterial pathogens129, such as Aspergillus spp., Blastomyces spp. and 
Legionella spp., and it highlights two important issues. First, as pathogens adapt to 
changing environments due to global warming, we may see additional instances of 
accidental pathogenesis through the selection of new traits that promote both 
environmental survival and pathogenesis in humans. Second, we should be alert to the 
fact that changes in human behaviour and habitat use (for example, increased tourist 
access to remote rainforest or desert areas) may expose us to new potential pathogens that 
have been predisposed to infection via selection through environmental predators.
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Box 4
Host immunity: too little or too much?
Poor pro-inflammatory responses to cryptococci, such as those in patients with advanced 
HIV infection, lead to life-threatening meningoencephalitis. Consequently, immune 
profiling of the peripheral T cell responses and cerebrospinal fluid cytokines from 
patients has shown that those mounting a pro-inflammatory immune response are more 
likely to clear the pathogen and survive infection66. Moreover, augmenting pro-
inflammatory immune responses using adjunctive interferon-γ (IFNγ) improves fungal 
clearance130. Conversely, individuals producing antibodies that block the activity of 
cytokines and interfere with appropriate pro-inflammatory responses are known to be at 
enhanced risk of infection131.
Although a potent immune response to Cryptococcus spp. is clearly essential for fungal 
clearance, too strong a response can also be harmful. For instance, a low level of anti-
inflammatory activity driven by both T helper 2 (TH2) and regulatory T 
cells132, 133 prevents complete immune paralysis. This is also the case for the classical 
antifungal cytokine interleukin-17 (IL-17), which is essential for resistance to 
cryptococcosis134, but the effects of which must also be regulated by IL-23 to prevent 
damage to the host owing to excessive inflammation135. Thus, a ‘successful’ immune 
response to cryptococcal infection seems to be a complex blend of TH1, TH2 and TH17 
responses, which must be counter-regulated to prevent either runaway fungal growth or 
damaging levels of inflammation.
This crucial role for ‘restraining’ pro-inflammatory signalling is particularly highlighted 
by the problem of immune reconstitution inflammatory syndrome (IRIS). This life-
threatening inflammatory reaction occurs in some HIV-infected patients during 
antiretroviral therapy (ART) and is caused by an ‘overreaction’ of the newly reconstituted 
immune system to residual pathogen antigen. Consequently, the timing of clinical 
intervention is crucial; early introduction of ART is important to restore cell-mediated 
immunity; but if ART is introduced too early (during the initial 2 weeks following 
induction of antifungal treatment) at a time of high fungal load, the risk of death is 
increased136. Development of IRIS is particularly likely in patients who mount a poor 
initial pro-inflammatory response to cryptococcal infection, resulting in high residual 
antigen burden137. Coupled with an exaggerated baseline chemokine response in the 
central nervous system (CNS), this results in aberrant CNS immune responses following 
ART initiation, resulting in IRIS.
Excessive inflammation can also occur following withdrawal of immune suppression in 
solid organ transplant recipients, as well as in apparently immunocompetent patients. In 
such situations, steroids are often administered alongside antifungals. It remains unclear, 
however, whether steroids are beneficial in other contexts: a multi-centre clinical trial to 
address this issue (investigating the effect of adjunctive dexamethasone in patients with 
HIV-associated cryptococcal meningoencephalitis) has been terminated early and results 
are awaited138.
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Figure 1. Inflammatory signalling in response to cryptococcal infection
Cryptococci, which can assume a titan cell morphology, inevitably shed microbial molecules 
that contain pathogen-associated molecular patterns (PAMPs). Such fungal molecules are 
typically components of the cell wall or capsule such as β-glucan, chitin or 
glucuronoxylomannan (GXM), which are detected by immune sentinel cells, most notably 
dendritic cells (DCs). DC activation then summons T cells, inducing CD4+ T cells to secrete 
cytokines that activate a T helper cell 1 (TH1) response (including the secretion of 
interleukin-12 (IL-12) and IL-23). TH1 cells produce pro-inflammatory cytokines (such as 
interferon-γ (IFNγ)), which ultimately control fungal infection. However, some fungal 
PAMPs can influence DC activation, including modulating the levels of major 
histocompatibility complex class II (MHC II) or of nuclear factor-κB (NF-κB) signalling. 
This activates a TH2 response (mediated by the production of cytokines such as IL-4 and 
IL-33); this anti-inflammatory environment affects macrophage activation (M1 classic 
activation and M2 alternative activation) and the ability of macrophages to mediate fungal 
clearance.
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Figure 2. Infection establishment and dissemination with in the human host
Cryptococcal cells typically enter the human host through the lung (bottom). There, they are 
recognized by patrolling phagocytes but can avoid uptake either by growing into very large 
titan cells, or by relying on the antiphagocytic properties of the fungal capsule. If uptake 
occurs, however, cryptococci can survive and persist in phagocytes. For most strains, a 
failure in host immune function is then required to allow intracellular proliferation. 
However, the unusual Pacific Northwest outbreak (PNO) strains of Cryptococcus gattii can 
proliferate in immunocompetent host cells by exploiting a poorly characterized ‘division of 
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labour’ mechanism: in response to reactive oxygen species generated by the phagocyte, 
some cryptococcal cells acquire an unusual morphology characterized by extensive 
tubularization of their mitochondria, which increases survival of neighbouring cells (via a 
mechanism that remains unclear). Cryptococcus spp. proliferation within phagocytes 
ultimately leads either to host cell lysis or to a nonlytic escape mechanism termed 
vomocytosis. Upon replication in the lung, cryptococci are able to disseminate to other 
tissues, including the central nervous system (CNS). Entry into the CNS can occur in three 
ways: by squeezing between host endothelial cells (paracytosis), which involves the fungal 
protease Mpr1 and the enzyme urease (which probably weakens the endothelial vessel wall 
to facilitate entry); by moving directly through endothelial cells (transcytosis), in a process 
that is mediated by hyaluronic acid in the fungal capsule and the host receptor CD44; or by 
‘hitching a ride’ within migrating phagocytes, through what is known as the ‘Trojan horse’ 
hypothesis. BBB, blood–brain barrier.
May et al. Page 29
Nat Rev Microbiol. Author manuscript; available in PMC 2017 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Current and future therapies for cryptococcosis
Schematic representation of a cryptococcal cell, showing key current and potential 
therapeutic targets and examples of antifungal drugs acting at each site. Drugs in current 
clinical use are shown in red, new drugs in blue and repurposed drugs in green. The three 
classes of antifungal agents currently used to treat cryptococcosis are polyenes (such as 
amphotericin B), azoles (such as fluconazole) and the pyrimidine analogue flucytosine (5-
FC). Amphotericin B deoxycholate (AmBd) acts by binding to ergosterol in the cryptococcal 
cell wall, generating pores in the cell membrane, and by inducing cell death by oxidative 
damage. 5-FC is deaminated by the fungal enzyme cytosine deaminase into 5-fluorouracil 
(5-FU), which then inhibits thymidylate synthetase and blocks DNA synthesis, or is 
converted into 5-fluorouridine triphosphate, which is incorporated into RNA and disrupts 
protein synthesis. Fluconazole inhibits the fungal cytochrome P450 enzyme 14α-
demethylase, which is required for conversion of lanosterol to ergosterol, an essential 
component of the fungal cell membrane. E1210 inhibits the synthesis of the cell wall 
component glycosylphosphatidylinositol (GPI)-anchored mannoproteins. VT-1129 blocks 
the activity of CYP51, an essential enzyme in the pathway to produce ergosterol. The 
arlyamidine T-2307 targets the fungal mitochondrial membrane. Tamoxifen (an oestrogen 
antagonist that is used in the treatment of breast cancer) targets calmodulin, and the 
antidepressant sertraline seems to target fungal protein synthesis through an unknown 
mechanism.
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